Alzheimer’s Disease Pipeline Analysis, 2022 | Latest FDA and EMA Approvals, Clinical Trials, Emerging Therapies | Biogen/Eisai (Lecanemab/BAN2401), Alector (AL044), Axsome (AXS-05), BioVie (NE3107)

Alzheimer’s Disease Pipeline Analysis, 2022 | Latest FDA and EMA Approvals, Clinical Trials, Emerging Therapies | Biogen/Eisai (Lecanemab/BAN2401), Alector (AL044), Axsome (AXS-05), BioVie (NE3107)
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Alzheimer’s Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Alzheimer’s Disease Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Alzheimer’s Disease Market. 

The Alzheimer’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Alzheimer’s Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Alzheimer’s Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer’s Disease Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Alzheimer’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

DelveInsight’s report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Key Developments in the Alzheimer’s Disease Therapeutics Market

• On September 27, 2022, Eisai and Biogen reported positive topline results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab (development code: BAN2401). Lecanemab is an investigational anti-amyloid beta (Aβ) protofibril antibody designed for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. Earlier in July 2022, the US FDA accepted Eisai’s Biologics License Application (BLA) for lecanemab under the accelerated approval pathway and granted Priority Review. 

• On September 12, 2022, Alector (Nasdaq: ALEC) announced the initiation of the first-in-human Phase 1 trial of AL044. AL044 is a function-modulating biologic targeting MS4A, a brain immune checkpoint molecule, and a genetic risk factor for Alzheimer’s disease (AD). 

• On September 08, 2022, Axsome Therapeutics NASDAQ: AXSM) announced that it had enrolled the first patient in the ADVANCE-2 trial of AXS-05. AXS-05 is an investigational treatment for Alzheimer’s disease (AD) agitation.

• On September 07, 2022, BioVie (NASDAQ: BIVI) announced topline results from an investigator-Sponsored Phase 2 clinical trial of NE3107 for the treatment of Alzheimer’s Disease (AD).

Learn How the Ongoing Clinical & Commercial Activities will Affect the Alzheimer’s Disease Therapeutic Segment:

Alzheimer’s Disease Therapeutics Landscape

There are approx. 100+ key companies which are developing therapies for Alzheimer’s Disease (AD). Currently, Eisai has its Alzheimer’s Disease (AD) drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Alzheimer’s Disease (AD) Therapeutic Market include:

Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Neurimmune, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Otsuka Pharmaceutical, AZ Therapies, Chugai Pharmaceuticals, Reviva Pharmaceutical, Anavex Life Sciences, Athira Pharma, Time Therapeutics, BioArctic AB, Prilenia Therapeutics, Denali Therapeutics Inc., and many others

Alzheimer’s Disease (AD) Drugs Covered in the report include:

• BAN2401

• Gantenerumab

• RP5063


• Tricaprilin

• Tricaprilin

• Brexpiprazole

• Aducanumab (BIIB037)

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Alzheimer’s Disease Current Treatment Patterns

4. Alzheimer’s Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Alzheimer’s Disease Late Stage Products (Phase-III)

7. Alzheimer’s Disease Mid-Stage Products (Phase-II)

8. Alzheimer’s Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Alzheimer’s Disease Discontinued Products

13. Alzheimer’s Disease Product Profiles

14. Key Companies in the Alzheimer’s Disease Market

15. Key Products in the Alzheimer’s Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Alzheimer’s Disease Unmet Needs

18. Alzheimer’s Disease Future Perspectives

19. Alzheimer’s Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Myelofibrosis Market

“Myelofibrosis Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Myelofibrosis Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States